Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Mutation employing a chemical mutagenic agent
Reexamination Certificate
2011-02-22
2011-02-22
Kosar, Andrew D (Department: 1654)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Mutation employing a chemical mutagenic agent
C435S007710
Reexamination Certificate
active
07892833
ABSTRACT:
Compounds can be used to act as inhibitors of enzymes having histone deacetylase activity for the medical therapy of conditions which predispose a person for the development of a disease, such as but not limited to cancer, inflammatory or metabolic diseases. Such conditions are linked to genetically inherited mutations of crucial genes which predispose a person with this condition to develop the disease phenotype. Thus, such compounds can be used for a suppressive therapeutic approach—the SUPPRESSION THERAPY—in order to inhibit or delay the onset or progression of the genetically predisposed disorder. Furthermore, a clinically used medicament can be manufactured for the SUPPRESSION THERAPY of such inherited predisposing conditions.
REFERENCES:
patent: 2005/0038113 (2005-02-01), Groner et al.
patent: 2006/0160897 (2006-07-01), Pelicci et al.
patent: 2008/0207724 (2008-08-01), Mink et al.
patent: 2009/0186809 (2009-07-01), Hentsch et al.
patent: EP-1293205 (2001-09-01), None
patent: 1 293 205 (2003-03-01), None
patent: WO00/66096 (2000-11-01), None
patent: WO02/102989 (2002-12-01), None
patent: WO2004/017996 (2004-03-01), None
Romeo-Gimenez, 2008, Int. J. Cancer, 122, 1422-1425.
Gottlicher, 2001, The EMBO Journal, 20, 6969-6978.
Truta, 2005, Familial Cancer, 4, 127-133.
Varesco, 2004, Tech Coloproctol, 8, S305-S308.
Bougatef, 2007, Gastroenterologie Clinique et Biologique, 31, 1062-1066 (Abstract only), 2 pages.
Shoji, 1993, Surgery, 113, 560-563.
[Retrived from] http://web.archive.org/web/20020417140826/http://www.genetichealth.com/CRC—FAP—A—Hereditary—Syndrome.shtml, 2002, 3 pages [Retrieved on Jul. 27, 2009].
Henderson, 2002, The Journal of Biological Chemistry, 277, 24258-24264.
International Preliminary Report on Patentability for PCT Appl. No. PCT/EP2004/006797 (Jan. 3, 2006).
Abdul, M., et al., “Inhibition by Anticonvulsants of Prostate-specific Antigen and Interleukin-6 Secretion by Human Prostate Cancer Cells,” Anticancer Res. 2001;21:2045-2048.
Mirnikjoo, B., et al., “Protein Kinase Inhibition by ω-3 Fatty Acids,” J. Biol. Chem. 2001;276(14):10888-10896.
Murphy, D. G., et al., “Inhibition Studies on Chicken Muscle Aldose Reductase,” Biochem. Pharmacol. 1985;34(16):2961-2965.
Olsen, C. M., et al., “Antiepilectic drugs inhibit cell growth in the human breast cancer cell line MCF7,” Mol. Cell. Endocrinol. 2004;213:173-179.
Papdimitriou, A., et al., “Late Onset Lipid Storage Myopathy Due to Multiple Acyl CoA Dehydrogenase Deficiency Triggered by Valproate,” Neuromus. Dis. 1991;1(4):247-252.
Park-Matsumoto, Y., et al., “Valproate induced lupus-like syndrome,” J. Neurol. Sci. 1996;143:185-186.
Poulsom, R., “Inhibition of Hexonate Dehydrogenase and Aldose Reductase from Bovine Retina by Sorbinil, Statil, M79175 and Valproate,” Biochem. Pharmcol. 1986;35(17):2955-2959.
Sims, K. B., “Von Hippel-Lindau disease: gene to bedside,” Curr. Op. Neurol. 2001;14:695-703.
Song, C. H., et al., “Successful Treatment of Steroid-Resistant Chorea Associated with Lupus by Use of Valproic Acid and Clonidine-HCL Patch,” Clin. Ped. 1997;36(11):659-662.
Turnbull, D. M., et al., “The Effect of Valproate on Blood Metabolite Concentrations in Spontaneously Diabetic, Ketoacidotic, BB/E Wistar Rats,” Diabetes Res. 1985;2:45-48.
Xiao, T., et al., “Inhibition of Rabbit Dermal Fibroblast Proliferation with Natrii Valproas,” Database Biosis [Online], Bioscience Information Service, Philadelphia, PA, US; 1992; Database accession No. 1992:502361 abstract & Hunan Yike Daxue Xuebao, vol. 17, No. 2, pp. 173-175.
International Search Report for PCT App. No. PCT/EP2004/006797 (Feb. 11, 2005).
Written Opinion for PCT App. No. PCT/EEP2004/006797.
Hentsch Bernd
Hövelmann Sascha
Martin Elke
Maurer Alexander B.
Raab Monika
Cermak Shelly Guest
Cermak Nakajima LLP
Gudibande Satyanarayana R
Kosar Andrew D
TopoTarget Germany AG
LandOfFree
Using inhibitors of histone deacetylases for the suppression... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Using inhibitors of histone deacetylases for the suppression..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Using inhibitors of histone deacetylases for the suppression... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2627358